BRAF and astrocytoma (excluding glioblastoma): In an effort to identify new therapeutic options for BRAF-mutated astrocytomas, Wang et al. characterized the pharmacokinetic profile of vemurafenib (Zelboraf), an oral BRAF inhibitor, in a Phase I study conducted on pediatric patients with recurrent or refractory BRAFV600E-mutated astrocytomas.